Who Owns Akebia Therapeutics Stock?
NASDAQ: AKBAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 41.38%
- Held by insiders
- 2.50%
- Institutional holders
- 210
- Institutions 41.4%
- Insiders 2.5%
- Public and other 56.1%
Who owns Akebia Therapeutics stock?
Institutional investors own about 41.4% of Akebia Therapeutics's shares, spread across 210 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 2.50% of AKBA.
The largest institutional holders are Blackrock Inc. (7.20%), Vanguard Capital Management LLC (4.08%) and AQR Capital Management, LLC (3.30%). Together, the top 10 institutions control 26.9% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their AKBA positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of AKBA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 19.99M | 7.20% | +6.9% |
| Vanguard Capital Management LLC | 11.32M | 4.08% | +1.4% |
| AQR Capital Management, LLC | 9.15M | 3.30% | +410.5% |
| Acadian Asset Management. LLC | 8.97M | 3.23% | +124.0% |
| Geode Capital Management, LLC | 6.35M | 2.29% | -5.7% |
| State Street Corporation | 5.30M | 1.91% | -1.8% |
| Jacobs Levy Equity Management, Inc. | 4.27M | 1.54% | +894.5% |
| Goldman Sachs Group Inc | 3.69M | 1.33% | +2.4% |
| Millennium Management Llc | 3.20M | 1.15% | +34.0% |
| Vanguard Portfolio Management LLC | 2.53M | 0.91% | +14.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of AKBA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 7.91M | 2.85% |
| iShares Trust-iShares Russell 2000 ETF | 6.83M | 2.46% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3.16M | 1.14% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.84M | 1.02% |
| iShares Trust-iShares Russell 2000 Growth ETF | 2.03M | 0.73% |
| Fidelity Commonwealth Trust II-Fidelity Enhanced Small Cap Core ETF | 1.95M | 0.70% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 1.48M | 0.53% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 1.31M | 0.47% |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 1.25M | 0.45% |
| iShares Trust-iShares Micro-Cap ETF | 816.91K | 0.29% |
Frequently asked questions
Who is the largest shareholder of Akebia Therapeutics?
Blackrock Inc. is the largest institutional shareholder of AKBA, owning 7.20% of shares outstanding (19.99M shares) as of its latest 13F filing.
What percentage of Akebia Therapeutics is owned by institutions?
Institutions own about 41.4% of AKBA shares and 42.4% of the public float.
How much of Akebia Therapeutics do insiders own?
Insiders, such as officers and directors, own about 2.50% of AKBA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.